Alnylam Pharmaceuticals
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT01814839
- Locations
- 🇬🇧
Clinical Site, London, United Kingdom
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT01617967
- Locations
- 🇸🇪
Clinical Trial Site, Umeå, Sweden
Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01559077
- Locations
- 🇬🇧
Clinical Site, London, United Kingdom
Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01437059
- Locations
- 🇬🇧
Clinical Site, London, United Kingdom
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
Phase 1
Completed
- Conditions
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT01158079
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Virgen del Rocio, Seville, Andalucia, Spain
Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01148953
- Locations
- 🇬🇧
Clinical Site, London, United Kingdom
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT01065935
- Locations
- 🇩🇪
Clinical Site, Leipzig, Germany
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT00882180
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00658086
- Locations
- 🇦🇺
Clinical Site, Perth, Western Australia, Australia
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT00496821
- Locations
- 🇺🇸
Alnylam Pharmaceuticals, Cambridge, Massachusetts, United States
© Copyright 2024. All Rights Reserved by MedPath